Detection of high mobility group A2 specific mRNA in the plasma of patients affected by epithelial ovarian cancer

Francesca Galdiero, Annunciata Romano, Rosa Pasquinelli, Sandro Pignata, Stefano Greggi, Emilia Vuttariello, Anna Maria Bello, Celeste Calise, Cono Scaffa, Carmela Pisano, Nunzia Simona Losito, Alfredo Fusco, Daniela Califano, Gennaro Chiappetta

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Ovarian cancer is the most lethal gynecological malignancy and the high mortality rate is associated with advanced-stage disease at the time of the diagnosis. In order to find new tools to make diagnosis of Epithelial Ovarian Cancer (EOC) at early stages we have analyzed the presence of specific HMGA2 mRNA in the plasma of patients affected by this neoplasm. HMGA2 overexpression represents a feature of several malignances including ovarian carcinomas. Notably, we detected HMGA2 specific mRNA in the plasma of 40 out 47 patients with EOC, but not in the plasma of healthy donors. All cases found positive for HMGA2 mRNA in the plasma showed HMGA2 protein expression in EOC tissues. Therefore, on the basis of these results, the analysis of circulating HMGA2 specific mRNA might be considered a very promising tool for the early diagnosis of EOC.

Original languageEnglish
Pages (from-to)19328-19335
Number of pages8
JournalOncotarget
Volume6
Issue number22
Publication statusPublished - 2015

Fingerprint

varespladib methyl
Messenger RNA
HMGA2 Protein
Ovarian Neoplasms
Early Diagnosis
Neoplasms
Tissue Donors
Carcinoma
Mortality
Ovarian epithelial cancer

Keywords

  • Circulating RNA
  • HMGA2
  • Ovarian Cancer
  • Plasma

ASJC Scopus subject areas

  • Oncology

Cite this

Detection of high mobility group A2 specific mRNA in the plasma of patients affected by epithelial ovarian cancer. / Galdiero, Francesca; Romano, Annunciata; Pasquinelli, Rosa; Pignata, Sandro; Greggi, Stefano; Vuttariello, Emilia; Bello, Anna Maria; Calise, Celeste; Scaffa, Cono; Pisano, Carmela; Losito, Nunzia Simona; Fusco, Alfredo; Califano, Daniela; Chiappetta, Gennaro.

In: Oncotarget, Vol. 6, No. 22, 2015, p. 19328-19335.

Research output: Contribution to journalArticle

@article{68ade65010104586953616ba4a54d670,
title = "Detection of high mobility group A2 specific mRNA in the plasma of patients affected by epithelial ovarian cancer",
abstract = "Ovarian cancer is the most lethal gynecological malignancy and the high mortality rate is associated with advanced-stage disease at the time of the diagnosis. In order to find new tools to make diagnosis of Epithelial Ovarian Cancer (EOC) at early stages we have analyzed the presence of specific HMGA2 mRNA in the plasma of patients affected by this neoplasm. HMGA2 overexpression represents a feature of several malignances including ovarian carcinomas. Notably, we detected HMGA2 specific mRNA in the plasma of 40 out 47 patients with EOC, but not in the plasma of healthy donors. All cases found positive for HMGA2 mRNA in the plasma showed HMGA2 protein expression in EOC tissues. Therefore, on the basis of these results, the analysis of circulating HMGA2 specific mRNA might be considered a very promising tool for the early diagnosis of EOC.",
keywords = "Circulating RNA, HMGA2, Ovarian Cancer, Plasma",
author = "Francesca Galdiero and Annunciata Romano and Rosa Pasquinelli and Sandro Pignata and Stefano Greggi and Emilia Vuttariello and Bello, {Anna Maria} and Celeste Calise and Cono Scaffa and Carmela Pisano and Losito, {Nunzia Simona} and Alfredo Fusco and Daniela Califano and Gennaro Chiappetta",
year = "2015",
language = "English",
volume = "6",
pages = "19328--19335",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "22",

}

TY - JOUR

T1 - Detection of high mobility group A2 specific mRNA in the plasma of patients affected by epithelial ovarian cancer

AU - Galdiero, Francesca

AU - Romano, Annunciata

AU - Pasquinelli, Rosa

AU - Pignata, Sandro

AU - Greggi, Stefano

AU - Vuttariello, Emilia

AU - Bello, Anna Maria

AU - Calise, Celeste

AU - Scaffa, Cono

AU - Pisano, Carmela

AU - Losito, Nunzia Simona

AU - Fusco, Alfredo

AU - Califano, Daniela

AU - Chiappetta, Gennaro

PY - 2015

Y1 - 2015

N2 - Ovarian cancer is the most lethal gynecological malignancy and the high mortality rate is associated with advanced-stage disease at the time of the diagnosis. In order to find new tools to make diagnosis of Epithelial Ovarian Cancer (EOC) at early stages we have analyzed the presence of specific HMGA2 mRNA in the plasma of patients affected by this neoplasm. HMGA2 overexpression represents a feature of several malignances including ovarian carcinomas. Notably, we detected HMGA2 specific mRNA in the plasma of 40 out 47 patients with EOC, but not in the plasma of healthy donors. All cases found positive for HMGA2 mRNA in the plasma showed HMGA2 protein expression in EOC tissues. Therefore, on the basis of these results, the analysis of circulating HMGA2 specific mRNA might be considered a very promising tool for the early diagnosis of EOC.

AB - Ovarian cancer is the most lethal gynecological malignancy and the high mortality rate is associated with advanced-stage disease at the time of the diagnosis. In order to find new tools to make diagnosis of Epithelial Ovarian Cancer (EOC) at early stages we have analyzed the presence of specific HMGA2 mRNA in the plasma of patients affected by this neoplasm. HMGA2 overexpression represents a feature of several malignances including ovarian carcinomas. Notably, we detected HMGA2 specific mRNA in the plasma of 40 out 47 patients with EOC, but not in the plasma of healthy donors. All cases found positive for HMGA2 mRNA in the plasma showed HMGA2 protein expression in EOC tissues. Therefore, on the basis of these results, the analysis of circulating HMGA2 specific mRNA might be considered a very promising tool for the early diagnosis of EOC.

KW - Circulating RNA

KW - HMGA2

KW - Ovarian Cancer

KW - Plasma

UR - http://www.scopus.com/inward/record.url?scp=84938863955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938863955&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 19328

EP - 19335

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 22

ER -